×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)

Avidity Biosciences (RNA) Stock Forecast, Price & News

$14.63
+1.22 (+9.10%)
(As of 05/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$12.93
$14.71
50-Day Range
$11.18
$20.50
52-Week Range
$11.02
$29.59
Volume
372,622 shs
Average Volume
262,860 shs
Market Capitalization
$728.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.36
30 days | 90 days | 365 days | Advanced Chart
Receive RNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Avidity Biosciences logo

About Avidity Biosciences

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RNA
Fax
N/A
Employees
125
Year Founded
N/A

Sales & Book Value

Annual Sales
$9.33 million
Book Value
$7.55 per share

Profitability

Net Income
$-118.01 million
Net Margins
-1,525.48%
Pretax Margin
-1,525.48%

Debt

Price-To-Earnings

Miscellaneous

Free Float
41,761,000
Market Cap
$728.03 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/10/2022
Today
5/27/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

568th out of 1,424 stocks

Pharmaceutical Preparations Industry

258th out of 681 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -













Avidity Biosciences (NASDAQ:RNA) Frequently Asked Questions

Is Avidity Biosciences a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avidity Biosciences stock.
View analyst ratings for Avidity Biosciences
or view top-rated stocks.

When is Avidity Biosciences' next earnings date?

Avidity Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Avidity Biosciences
.

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) posted its quarterly earnings results on Tuesday, May, 10th. The biotechnology company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.09. Avidity Biosciences had a negative net margin of 1,525.48% and a negative trailing twelve-month return on equity of 36.26%.
View Avidity Biosciences' earnings history
.

What price target have analysts set for RNA?

5 brokers have issued 12-month target prices for Avidity Biosciences' stock. Their forecasts range from $36.00 to $59.00. On average, they anticipate Avidity Biosciences' stock price to reach $49.60 in the next twelve months. This suggests a possible upside of 239.0% from the stock's current price.
View analysts' price targets for Avidity Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Avidity Biosciences' key executives?
Avidity Biosciences' management team includes the following people:
  • Dr. Troy Edward Wilson J.D., Ph.D., Co-Founder & Chairman (Age 53, Pay $65k)
  • Ms. Sarah Boyce, Pres, CEO & Director (Age 50, Pay $1M)
  • Mr. Michael F. MacLean, CFO & Chief Bus. Officer (Age 56, Pay $650.38k)
  • Dr. W. Michael Flanagan Ph.D., Chief Technical Officer (Age 60, Pay $1M)
  • Dr. Arthur A. Levin Ph.D., Chief Scientific Officer (Age 68, Pay $662.86k)
  • Mr. Joseph T. Baroldi, Consultant (Age 43, Pay $642.43k)
  • Prof. Mark E. Davis, Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s
  • Dr. Frank McCormick Ph.D., Scientific Founder & Member of Scientific Advisory Board (Age 72)
  • Ms. Kathleen Gallagher, Sr. VP of Corp. Communications & Investor Relations
  • Dr. John W. Wallen III, VP of Intellectual Property, Gen. Counsel & Sec. (Age 64)
What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

When did Avidity Biosciences IPO?

(RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO.

What is Avidity Biosciences' stock symbol?

Avidity Biosciences trades on the NASDAQ under the ticker symbol "RNA."

Who are Avidity Biosciences' major shareholders?

Avidity Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Aaron Wealth Advisors LLC (8.01%), BlackRock Inc. (6.56%), Vanguard Group Inc. (4.62%), RA Capital Management L.P. (4.36%), State Street Corp (3.30%) and Wellington Management Group LLP (2.28%). Company insiders that own Avidity Biosciences stock include Arthur A Levin and Rtw Investments, Lp.
View institutional ownership trends for Avidity Biosciences
.

Which major investors are selling Avidity Biosciences stock?

RNA stock was sold by a variety of institutional investors in the last quarter, including US Bancorp DE, Citigroup Inc., BlackRock Inc., Harbor Capital Advisors Inc., JPMorgan Chase & Co., Metropolitan Life Insurance Co NY, Northern Trust Corp, and TD Asset Management Inc..
View insider buying and selling activity for Avidity Biosciences
or view top insider-selling stocks.

Which major investors are buying Avidity Biosciences stock?

RNA stock was bought by a variety of institutional investors in the last quarter, including Aaron Wealth Advisors LLC, RA Capital Management L.P., Vanguard Group Inc., State Street Corp, Dimensional Fund Advisors LP, Walleye Capital LLC, Wellington Management Group LLP, and The Manufacturers Life Insurance Company .
View insider buying and selling activity for Avidity Biosciences
or or view top insider-buying stocks.

How do I buy shares of Avidity Biosciences?

Shares of RNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avidity Biosciences' stock price today?

One share of RNA stock can currently be purchased for approximately $14.63.

How much money does Avidity Biosciences make?

Avidity Biosciences has a market capitalization of $728.03 million and generates $9.33 million in revenue each year. The biotechnology company earns $-118.01 million in net income (profit) each year or ($2.910010) on an earnings per share basis.

How many employees does Avidity Biosciences have?

Avidity Biosciences employs 125 workers across the globe.

What is Avidity Biosciences' official website?

The official website for Avidity Biosciences is www.aviditybiosciences.com.

How can I contact Avidity Biosciences?

Avidity Biosciences' mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The biotechnology company can be reached via phone at 858-401-7900 or via email at [email protected].

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.